MyMedR

Displaying all 3 publications

Abstract:

Sort:

Fulltext Novel CE-CBCE feature extraction method for object classification using a low-density LiDAR point cloud

Mohd Romlay MR, Mohd Ibrahim A, Toha SF, De Wilde P, Venkat I

PLoS One, 2021;16(8):e0256665.
PMID: 34432855 DOI: 10.1371/journal.pone.0256665

Low-end LiDAR sensor provides an alternative for depth measurement and object recognition for lightweight devices. However due to low computing capacity, complicated algorithms are incompatible to be performed on the device, with sparse information further limits the feature available for extraction. Therefore, a classification method which could receive sparse input, while providing ample leverage for the classification process to accurately differentiate objects within limited computing capability is required. To achieve reliable feature extraction from a sparse LiDAR point cloud, this paper proposes a novel Clustered Extraction and Centroid Based Clustered Extraction Method (CE-CBCE) method for feature extraction followed by a convolutional neural network (CNN) object classifier. The integration of the CE-CBCE and CNN methods enable us to utilize lightweight actuated LiDAR input and provides low computing means of classification while maintaining accurate detection. Based on genuine LiDAR data, the final result shows reliable accuracy of 97% through the method proposed.
1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration

Chandrasekhar J, Zeebregts D, Kalkman DN, Sartori S, Roumeliotis A, Aquino MB, et al.

Cardiovasc Revasc Med, 2020 12;21(12):1542-1547.
PMID: 32507695 DOI: 10.1016/j.carrev.2020.05.002

BACKGROUND: Small vessel diameter is associated with higher risk of target lesion revascularization (TLR) after percutaneous coronary intervention (PCI). The COMBO sirolimus-eluting biodegradable-polymer stent has a proprietary anti-CD34 antibody layer to enhance homogeneous endothelialization, which may be advantageous in treating small vessels.
OBJECTIVE: We examined for differences in 1-year clinical outcomes after PCI by maximum implanted stent diameter from the COMBO collaboration.
METHODS: The COMBO collaboration (n = 3614) is a patient-level pooled dataset of patients undergoing PCI with COMBO stents in the MASCOT and REMEDEE multicenter registries. Stent diameter was available in 3590 (99.3%) patients. We compared patients receiving COMBO stents <3 mm versus ≥3 mm. The primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, target vessel-myocardial infarction (TV-MI) or clinically driven TLR. Secondary outcomes included stent thrombosis (ST). Adjusted outcomes were assessed using Cox regression methods.
RESULTS: The study included 792 (22%) patients with small stents <3 mm and 2798 (78%) patients with large stents ≥3 mm. Small stent patients included more women with lower body mass index and higher prevalence of diabetes but similar prevalence of acute coronary syndrome. Risk of 1-year TLF was similar in small and large stent groups (4.4% vs. 3.8%, HR 1.12, 95% CI 0.74-1.72, p = 0.58). There were no differences in the rates of cardiac death (1.7% vs. 1.5%, p = 0.74), TV-MI (1.4% vs. 1.2%, p = 0.58) or TLR (2.7% vs. 2.1%, p = 0.31). Definite or probable ST occurred in 1.3% of the small stent and 0.7% of the large stent PCI patients, p = 0.14, HR 2.13, 95% CI 0.93-5.00, p = 0.07.
CONCLUSIONS: One-year ischemic outcomes after COMBO PCI were similar irrespective of stent diameter in this all-comers international cohort.
One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration

Chandrasekhar J, de Winter VC, Kalkman DN, Sartori S, Chandiramani R, Aquino MB, et al.

Cardiovasc Drugs Ther, 2021 04;35(2):309-320.
PMID: 33515411 DOI: 10.1007/s10557-020-07087-6

PURPOSE: The COMBO biodegradable polymer sirolimus-eluting stent includes endothelial progenitor cell capture (EPC) technology for rapid endothelialization, which may offer advantage in acute coronary syndromes (ACS). We sought to analyze the performance of the COMBO stent by ACS status and ACS subtype.
METHODS: The COMBO collaboration (n = 3614) is a patient-level pooled dataset from the MASCOT and REMEDEE registries. We evaluated outcomes by ACS status, and ACS subtype in patients with ST segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) versus unstable angina (UA). The primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Secondary outcomes included stent thrombosis (ST).
RESULTS: We compared 1965 (54%) ACS and 1649 (46.0%) non-ACS patients. ACS presentations included 40% (n = 789) STEMI, 31% (n = 600) NSTEMI, and 29% (n = 576) UA patients. Risk of 1-year TLF was greater in ACS patients (4.5% vs. 3.3%, HR 1.51 95% CI 1.01-2.25, p = 0.045) without significant differences in definite/probable ST (1.1% vs 0.5%, HR 2.40, 95% CI 0.91-6.31, p = 0.08). One-year TLF was similar in STEMI, NSTEMI, and UA (4.8% vs 4.8% vs. 3.7%, p = 0.60), but definite/probable ST was higher in STEMI patients (1.9% vs 0.5% vs 0.7%, p = 0.03). Adjusted outcomes were not different in MI versus UA patients.
CONCLUSIONS: Despite the novel EPC capture technology, COMBO stent PCI was associated with somewhat greater risk of 1-year TLF in ACS than in non-ACS patients, without significant differences in stent thrombosis. No differences were observed in 1-year TLF among ACS subtypes.

Filters

Please provide feedback to Administrator ([email protected])

External Links